LY2510924

Phase 2Small molecule

Eli Lilly

LY2510924 is one of 112 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Type 2 DiabetesActive, not recruiting

Small Cell Lung CarcinomaPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Preclinical

31 2

LY2510924

Eli Lilly

Phase 2

4 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Glargine

Eli Lilly

Preclinical

8 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 7

Forxiga

AstraZeneca

Preclinical

3 8

Lovaza

AstraZeneca

Preclinical

1 9

Acipimox

Boehringer Ingelheim

Preclinical

2 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Solid Tumors1 trial

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT02737072·9 enrolled

Renal Cell Carcinoma1 trial

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT01391130·110 enrolled

Acute Myeloid Leukemia1 trial

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02652871·36 enrolled

Small Cell Lung Carcinoma1 trial

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01439568·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for LY2510924. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY2510924 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY2510924. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY2510924

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Solid Tumors1 trial

Renal Cell Carcinoma1 trial

Acute Myeloid Leukemia1 trial

Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News